Skip to content
DataLookout
Menu

NCT06644781

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words
    • Trial sites expanded: 132 → 168 locations
    • Secondary endpoints: details revised at 4 of 11 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Minor Trial sites expanded: 88 → 132 locationsv9
  3. Minor Study sites: 46 to 88v8
  4. Minor Study sites: 20 to 46v7
  5. Minor Study sites: 15 to 20v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 9 to 15v5
  2. Minor Study sites: 6 to 9v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Start date changed from estimate of Feb 28, 2025 to Mar 27, 2025
    v3
  4. Notable Eligibility criteria shortened, about 136 wordsv2 Show 5 more changesShow less
    • Primary completion date: May 30, 2029 to Jun 1, 2028
    • Study completion date: Oct 30, 2029 to Nov 1, 2029
    • Interventions: Docetaxel (Drug), Ifinatamab deruxtecan (Drug), Irinotecan (Drug), Paclitaxel (Drug) to Docetaxel (Drug), Ifinatamab deruxtecan (Drug), Irinotecan hydrochloride (HCl) (Drug), Paclitaxel (Drug)
    • Secondary endpoints: details revised at 9 of 11 entries
    • Study title expanded, about 5 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: From the date of randomization to the date of death due to any cause, up to approximately 54 months

Secondary (11)

Progression-free survival (PFS)
Objective Response Rate (ORR)
Duration of Response (DoR)
Disease Control Rate (DCR)
Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire Score (EORTC QLQ-C30)
Show 6 moreShow less
Change from baseline in European Organisation for Research and Treatment of Cancer Esophageal Cancer Module Score (EORTC OES18)
Incidence of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Percentage of Participants Who Have Treatment-emergent ADA
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for I-DXd
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for Total Anti-B7-H3 Antibody
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for MAAA-1181a

Arms and interventions

I-DXdExperimental

Participants who are randomized to receive an intravenous infusion of I-DXd 12 mg/kg on Day 1 of every 21-day cycle (Q3W).

Investigator's Choice of Chemotherapy (ICC)Active comparator

Participants who are randomized to receive an intravenous infusion of investigator's choice of chemotherapy (docetaxel, paclitaxel, and irinotecan HCl).

Drugs: Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)

Sites

168 sites in 17 countries

China 30, France 17, Japan 17, Spain 14, United States 14, Germany 11, Italy 11, United Kingdom 11, South Korea 10, Romania 7, Belgium 6, Taiwan 5, Netherlands 4, Denmark 3, Norway 3, Poland 3, Sweden 2